AKYNZEO (palonosetron + netupitant), combination setron
GASTROENTEROLOGY - ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Oct 04 2017
Reason for request
No clinical benefit demonstrated in prevention of nausea and vomiting after highly emetogenic chemotherapy compared with the standard treatment (setron + aprepitant + corticosteroid)
Insufficient clinical benefit after moderately emetogenic chemotherapy, in the absence of clinical data
- AKYNZEO has marketing authorisation in the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy and moderately emetogenic chemotherapy.
- In the context of a highly emetogenic chemotherapy or anthracycline/cyclophosphamide, the available data do not make it possible to assess the benefit of AKYNZEO compared with the standard treatment (setron + corticosteroid + aprepitant) in the prevention of nausea and vomiting. The transferability and the impact on morbidity and mortality and on quality of life have not been demonstrated to date.
- Its clinical benefit after a moderately emetogenic chemotherapy has not been established.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments